| Status | Suspended |
| Decision | Selected |
| Process | STA pre-2018 |
| Referral date | 01 April 2010 |
| Topic area |
|
| Description |
Scoped within batch 10 |
Provisional Schedule
| Closing date for invited submissions / evidence submission: | TBC |
| 1st appraisal committee meeting: | TBC |
Project Team
| Communications manager: | Tonya Gillis |
| Executive Lead: | Andrew Dillon |
| Project manager: | Jeremy Powell |
| Technical Lead: | Whitney Miller |
Stakeholders
| Manufacturers/sponsors | Rituximab (Roche Products) |
| Others | Bradford and Airedale Teaching PCT |
| Department of Health | |
| NHS Hertfordshire | |
| Welsh Assembly Government | |
| Patient/carer groups | Action on Pain |
| Afiya Trust | |
| Arthritic Association | |
| Arthritis & Musculoskeletal Alliance (ARMA) | |
| Arthritis Care | |
| Black Health Agency | |
| Chinese National Healthy Living Centre | |
| Counsel and Care | |
| Equalities National Council | |
| Leonard Cheshire Disability | |
| Muslim Council of Britain | |
| Muslim Health NetworkNational Rheumatoid Arthritis Society | |
| Pain Concern | |
| Pain Relief Foundation | |
| Royal Association for Disability & Rehabilitation (RADAR) | |
| South Asian Health Foundation | |
| Specialised Healthcare Alliance | |
| Professional groups | British Association for Services to the Elderly |
| British Geriatrics Society | |
| British Health Professionals in Rheumatology | |
| British Institute of Musculoskeletal Medicine | |
| British Institute of Radiology | |
| British Orthopaedic Association | |
| British Pain Society | |
| British Society for Rheumatology | |
| British Society of Rehabilitation Medicine | |
| Physiotherapy Pain Association | |
| Primary Care Rheumatology Society | |
| Rheumatoid Arthritis Surgical Society | |
| Royal College of Anaesthetists | |
| Royal College of General Practitioners | |
| Royal College of Nursing | |
| Royal College of Pathologists | |
| Royal College of Physicians | |
| Royal College of Radiologists | |
| Royal College of Surgeons | |
| Royal Pharmaceutical Society | |
| Royal Society of Medicine â?? Intellectual Disabilities Forum | |
| Society and College of Radiographers | |
| United Kingdom Clinical Pharmacy Association | |
| Comparator manufacturer(s) | AAH Pharmaceuticals (azathioprine, sulfasalazine, penicillamine) |
| Abbott Laboratories (adalimumab) | |
| Actavis (azathioprine, sulfasalazine, penicillamine) | |
| Almus Pharmaceuticals (sulfasalazine) | |
| Arrow Generics (azathioprine) | |
| AstraZeneca (chloroquine) | |
| Focus Pharmaceuticals (azathioprine) | |
| Genesis Pharmaceuticals (sulfasalazine) | |
| GlaxoSmithKline (azathioprine) | |
| Kent Pharmaceuticals (azathioprine, sulfasalazine, penicillamine) | |
| Metwest Pharmaceuticals (sulfasalazine) | |
| Mylan (azathioprine, sulfasalazine, penicillamine) | |
| Novartis (ciclosporin) | |
| Pfizer (sulfasalazine) | |
| Rosemont Pharmaceuticals (sulfasalazine) | |
| Sandoz (azathioprine) | |
| Sanofi Aventis (hydroxychloroquine, leflunomide, sodium aurothiomalate) | |
| Schering-Plough (infliximab, golimumab) | |
| Teva UK (azathioprine, sulfasalazine, penicillamine) | |
| Tillomed Laboratories (azathioprine) | |
| UCB Pharma (certolizumab pegol) | |
| Wyeth Pharmaceuticals (etanercept) | |
| Evidence Review Group | West Midlands Health Technology Assessment Collaboration |
| National Institute for Health Research Health Technology Assessment Programme | |
| Associated Guideline Groups | |
| National Clinical Guideline Centre | |
| Associated Public Health Groups | |
| None | |
| General | Board of Community Health Councils in Wales |
| British National Formulary | |
| Care Quality Commission | |
| Commissioning Support Appraisals Service | |
| Department of Health, Social Services and Public Safety for Northern Ireland | |
| Medicines and Healthcare products Regulatory Agency | |
| National Association of Primary Care | |
| NHS Alliance | |
| NHS Commercial Medicines Unit | |
| NHS Confederation | |
| NHS Quality Improvement Scotland | |
| Public Health Wales NHS Trust | |
| Scottish Medicines Consortium | |
| Relevant research groups | Arthritis Research Campaign |
| Chronic Pain Policy Coalition | |
| MRC Clinical Trials Unit | |
| National Institute for Health Research | |
| Policy Research Institute on Ageing and Ethnicity | |
| Research Institute for the Care of Older People |
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 22 March 2011 |
The manufacturer has informed us that they will not be seeking a license for this particular indication at the present time. NICE has therefore decided to suspend this appraisal from its current work programme. As this topic has been referred to the Institute we will continue to monitor any development and will update interested parties if the situation changes.” |
For further information on our processes and methods, please see our CHTE processes and methods manual